MiRXES specializes in providing clinical diagnostic tools that seek to revolutionize early cancer detection in clinical examinations with its best-in-class MicroRNA quantification platform. Its vision is to create accurate, affordable and actionable molecular diagnostic tests to improve cancer management.
Leading the revolution in early cancer diagnostic
Venturecraft Holdings, trading as Venturecraft Group, is a private investment group and venture capital platform that provides working capital, market access assistance and other essential resources to growth-stage and late-stage enterprises in the MedTech, BioTech and Digital Health sectors.
Venturecraft Group is also an appointed accelerator under SPRING Singapore’s Sector Specific Accelerator Programme. It has a regional presence in Asia across Singapore, China and Taiwan, and operates two incubators located in Singapore (the JTC Launchpad @ one-north) and China (Hangzhou Economic and Technological Development Area (HEDA)).